Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

UNITED STATES (Flag Family Media) - Minnesota sees one case of infant botulism linked to recalled baby formula. The case of the rare but serious illness has been seen in 15 cases across 12 states. The ...

Formula 1 has entered into a new five-year media rights deal with Apple that will bring all F1 races to Apple TV for viewers in the United States beginning in 2026, it was announced on Friday, Oct. 17 ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Formula 1's $2.5 billion in revenue is driven by record attendance and global viewership. Hiranmayi Srinivasan is a former Associate Editor for Investopedia. She covered personal finance topics such ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

Feeding a baby generally comes with a steep learning curve, no matter if it’s your first or your fourth, and regardless of the feeding method you choose. That’s because every baby is different—even ...

AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...